Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-mesothelin T-cell engaging bispecific antibody JNJ-79032421

A bispecific T-cell engager (TCE) and bispecific antibody directed against both the tumor-associated antigen (TAA) mesothelin (MSLN) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-mesothelin T-cell engaging bispecific antibody JNJ-79032421 targets and binds to MSLN expressed on tumor cells and to CD3 expressed on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to MSLN-expressing tumor cells, which results in the CTL-mediated death of MSLN-expressing tumor cells. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.
Synonym:anti-mesothelin/anti-CD3 bispecific antibody JNJ-79032421
anti-MSLN T-cell engager JNJ-79032421
anti-MSLN TCE JNJ-79032421
Code name:JNJ 2421
JNJ 79032421
JNJ-2421
JNJ-79032421
JNJ2421
JNJ79032421
Search NCI's Drug Dictionary